Selected research
Industry Research
HIV Vaccines Industry Research Report 2026
Market perspective
The global HIV Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the HIV Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the HIV Vaccines market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the HIV Vaccines market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of HIV Vaccines include Sanofi, Glaxosmithkline, Paxvax, Janssen Global Services, Inovio Pharmaceuticals, Geovax, Genecure, Bionor Pharma and Argos Therapeutics. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global HIV Vaccines market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to HIV Vaccines.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
HIV Vaccines Market by Company
Sanofi
Glaxosmithkline
Paxvax
Janssen Global Services
Inovio Pharmaceuticals
Geovax
Genecure
Bionor Pharma
Argos Therapeutics
HIV Vaccines Segment by Type
Phase I
Phase II
Phase III
HIV Vaccines Segment by Application
Research Institute
Others
HIV Vaccines Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of HIV Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of HIV Vaccines companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Phase I
- Phase II
- Phase III
Applications
- Research Institute
- Others
Companies covered
- Sanofi
- Glaxosmithkline
- Paxvax
- Janssen Global Services
- Inovio Pharmaceuticals
- Geovax
- Genecure
- Bionor Pharma
- Argos Therapeutics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 HIV Vaccines by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Phase I
- 2.2.3 Phase II
- 2.2.4 Phase III
- 2.3 HIV Vaccines by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Research Institute
- 2.3.3 Others
- 2.4 Assumptions and Limitations
3 HIV Vaccines Breakdown Data by Type
- 3.1 Global HIV Vaccines Historic Market Size by Type (2021-2026)
- 3.2 Global HIV Vaccines Forecasted Market Size by Type (2027-2032)
4 HIV Vaccines Breakdown Data by Application
- 4.1 Global HIV Vaccines Historic Market Size by Application (2021-2026)
- 4.2 Global HIV Vaccines Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global HIV Vaccines Market Perspective (2021-2032)
- 5.2 Global HIV Vaccines Growth Trends by Region
- 5.2.1 Global HIV Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 HIV Vaccines Historic Market Size by Region (2021-2026)
- 5.2.3 HIV Vaccines Forecasted Market Size by Region (2027-2032)
- 5.3 HIV Vaccines Market Dynamics
- 5.3.1 HIV Vaccines Industry Trends
- 5.3.2 HIV Vaccines Market Drivers
- 5.3.3 HIV Vaccines Market Challenges
- 5.3.4 HIV Vaccines Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top HIV Vaccines Players by Revenue
- 6.1.1 Global Top HIV Vaccines Players by Revenue (2021-2026)
- 6.1.2 Global HIV Vaccines Revenue Market Share by Players (2021-2026)
- 6.2 Global HIV Vaccines Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of HIV Vaccines Head Office and Area Served
- 6.4 Global HIV Vaccines Players, Product Type & Application
- 6.5 Global HIV Vaccines Manufacturers Established Date
- 6.6 Global HIV Vaccines Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America HIV Vaccines Market Size (2021-2032)
- 7.2 North America HIV Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America HIV Vaccines Market Size by Country (2021-2026)
- 7.4 North America HIV Vaccines Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe HIV Vaccines Market Size (2021-2032)
- 8.2 Europe HIV Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe HIV Vaccines Market Size by Country (2021-2026)
- 8.4 Europe HIV Vaccines Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific HIV Vaccines Market Size (2021-2032)
- 9.2 Asia-Pacific HIV Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific HIV Vaccines Market Size by Country (2021-2026)
- 9.4 Asia-Pacific HIV Vaccines Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America HIV Vaccines Market Size (2021-2032)
- 10.2 South America HIV Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America HIV Vaccines Market Size by Country (2021-2026)
- 10.4 South America HIV Vaccines Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa HIV Vaccines Market Size (2021-2032)
- 11.2 Middle East & Africa HIV Vaccines Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa HIV Vaccines Market Size by Country (2021-2026)
- 11.4 Middle East & Africa HIV Vaccines Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sanofi
- 12.1.1 Sanofi Company Information
- 12.1.2 Sanofi Business Overview
- 12.1.3 Sanofi Revenue in HIV Vaccines Business (2021-2026)
- 12.1.4 Sanofi HIV Vaccines Product Portfolio
- 12.1.5 Sanofi Recent Developments
- 12.2 Glaxosmithkline
- 12.2.1 Glaxosmithkline Company Information
- 12.2.2 Glaxosmithkline Business Overview
- 12.2.3 Glaxosmithkline Revenue in HIV Vaccines Business (2021-2026)
- 12.2.4 Glaxosmithkline HIV Vaccines Product Portfolio
- 12.2.5 Glaxosmithkline Recent Developments
- 12.3 Paxvax
- 12.3.1 Paxvax Company Information
- 12.3.2 Paxvax Business Overview
- 12.3.3 Paxvax Revenue in HIV Vaccines Business (2021-2026)
- 12.3.4 Paxvax HIV Vaccines Product Portfolio
- 12.3.5 Paxvax Recent Developments
- 12.4 Janssen Global Services
- 12.4.1 Janssen Global Services Company Information
- 12.4.2 Janssen Global Services Business Overview
- 12.4.3 Janssen Global Services Revenue in HIV Vaccines Business (2021-2026)
- 12.4.4 Janssen Global Services HIV Vaccines Product Portfolio
- 12.4.5 Janssen Global Services Recent Developments
- 12.5 Inovio Pharmaceuticals
- 12.5.1 Inovio Pharmaceuticals Company Information
- 12.5.2 Inovio Pharmaceuticals Business Overview
- 12.5.3 Inovio Pharmaceuticals Revenue in HIV Vaccines Business (2021-2026)
- 12.5.4 Inovio Pharmaceuticals HIV Vaccines Product Portfolio
- 12.5.5 Inovio Pharmaceuticals Recent Developments
- 12.6 Geovax
- 12.6.1 Geovax Company Information
- 12.6.2 Geovax Business Overview
- 12.6.3 Geovax Revenue in HIV Vaccines Business (2021-2026)
- 12.6.4 Geovax HIV Vaccines Product Portfolio
- 12.6.5 Geovax Recent Developments
- 12.7 Genecure
- 12.7.1 Genecure Company Information
- 12.7.2 Genecure Business Overview
- 12.7.3 Genecure Revenue in HIV Vaccines Business (2021-2026)
- 12.7.4 Genecure HIV Vaccines Product Portfolio
- 12.7.5 Genecure Recent Developments
- 12.8 Bionor Pharma
- 12.8.1 Bionor Pharma Company Information
- 12.8.2 Bionor Pharma Business Overview
- 12.8.3 Bionor Pharma Revenue in HIV Vaccines Business (2021-2026)
- 12.8.4 Bionor Pharma HIV Vaccines Product Portfolio
- 12.8.5 Bionor Pharma Recent Developments
- 12.9 Argos Therapeutics
- 12.9.1 Argos Therapeutics Company Information
- 12.9.2 Argos Therapeutics Business Overview
- 12.9.3 Argos Therapeutics Revenue in HIV Vaccines Business (2021-2026)
- 12.9.4 Argos Therapeutics HIV Vaccines Product Portfolio
- 12.9.5 Argos Therapeutics Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst